Developed by Pfizer, this daily oral pill uses a targeted dual-action mechanism to block the autoimmune attack on hair follicles. In the groundbreaking three-year ALLEGRO-LT study, nearly 90% of patients who achieved 80% or more scalp hair coverage at Month 12 maintained their regrowth all the way through 36 months of continuous treatment, with nearly 30% achieving complete, 100% scalp hair regrowth.
What Is It and How Does It Work?
Ritlecitinib (brand name Litfulo) is a once-daily oral capsule (50 mg dose) approved specifically for adults and adolescents aged 12 and older who suffer from severe alopecia areata. Alopecia areata is a chronic autoimmune condition where the body’s immune system gets “confused” and sends killer T-cells to assault healthy hair follicle bulbs, forcing hair to shed rapidly in patches or across the entire scalp.
The treatment works through a precise biological process called Dual JAK3 and TEC Family Kinase Inhibition:
-
Targeting the Attack Signals: Traditional steroids work like a sledgehammer, suppressing your entire immune system and causing broad side effects. Ritlecitinib acts as a selective signal jammer.
-
Dual Kinase Blockade: It specifically binds to and disables two distinct enzyme families inside immune cells: Janus Kinase 3 (JAK3) and the TEC kinase family.
-
Restoring Follicle Peace: These enzymes are the cellular transmitters that killer T-cells and natural killer (NK) cells use to send inflammatory attack signals (such as interleukin-15 and IL-21). By double-locking these pathways, ritlecitinib mutes the attack signal locally at the hair root, allowing the hair follicles to exit their forced dormancy and safely resume growing thick hair.
The Science: 3-Year Durability Data Confirmed by the SALT Score
The long-term trial results come from the ALLEGRO-LT study, which tracked adult and pediatric patients for up to 38 months of continuous therapy. To evaluate hair regrowth objectively, dermatologists used the standardized SALT score.
What is the SALT Score? The Severity of Alopecia Tool (SALT) score measures the exact percentage of hair loss across the scalp.
100 represents total scalp hair loss (100% baldness).
0 represents a completely full head of hair (0% hair loss / 100% coverage).
In clinical trials, reaching a SALT score of 20 or less (SALT ≤ 20) is the benchmark for success, meaning the patient has regrown 80% or more of their scalp hair.
The 36-to-38-month clinical findings demonstrated exceptional long-term efficacy:
-
90% Response Retention: Among patients who achieved 80% or more scalp coverage (SALT ≤ 20) at Month 12, an impressive 88.3% (observed) to 89.6% (LOCF) maintained this level of hair regrowth out to 3 years.
-
Complete Scalp Regrowth (SALT = 0): By Month 36, 29.8% of participants achieved complete, 100% scalp hair regrowth.
Read next
Whats the best shampoo for hair loss?
-
High Stability: Over 61% of patients who achieved complete scalp regrowth experienced zero subsequent relapses or increases in hair loss during the follow-up visits.
-
Eyebrow and Eyelash Improvements: The 3-year data confirmed sustained regrowth in facial hair, with 63.2% maintaining eyebrow coverage and 60.4% maintaining eyelash coverage.
-
Early Intervention Is Key: Multivariable regression modeling revealed that starting treatment earlier in the disease course significantly increases success rates. For instance, every 3-year delay in treating severe hair loss reduced the odds of achieving a full clinical response by 46.5%, proving that early intervention prevents permanent damage to the hair follicle microenvironment.
“We see retention of clinical benefit achieved at month 12 maintained at month 36 in approximately 90% of patients, but, again, we see achievement of SALT score zero, so 0% terminal scalp hair loss in about 30% of patients out at month 36… really, really important data and tells us a lot about what we can do or what we can expect with treatment with ritlecitinib, for our patients with severe alopecia areata.” — Dr. Brett King, Associate Professor of Dermatology at Yale University School of Medicine.
When Will It Be Available?
-
Regulatory Status: Ritlecitinib (Litfulo) is fully approved by the FDA (United States) and EMA (Europe) for adults and adolescents aged 12 years and older.
-
Availability: Because it is an approved medication, it is available now and can be prescribed immediately by specialist dermatologists.
How you can benefit from this treatment now
If you or a family member aged 12 or older are struggling with severe patchy or total autoimmune hair loss, the 3-year ALLEGRO-LT data provides clear, actionable steps today:
-
Schedule an Early Consultation: Because the study proved that a longer duration of untreated hair loss decreases response odds by nearly 47%, seeking early treatment from a dermatologist is critical to achieving maximum hair regrowth.
-
Explore Adolescent Options: Litfulo is uniquely approved for teenagers aged 12 and up. Parents of adolescents dealing with severe hair loss can discuss this dual-kinase inhibitor as a safe, FDA-approved long-term option.
-
Commit to Continuous Treatment: The 3-year data confirms that maintaining hair regrowth requires ongoing daily adherence. Because JAK inhibitors manage the autoimmune attack rather than curing the underlying genetic condition, staying consistent with your daily capsule ensures the “attack signals” remain blocked.
[cite: 1]